- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BELLUS Health To Update on Chronic Cough Drug Candidate
BELLUS Health announced it will host a “Key Opinion Leader” event focused on the treatment of a chronic cough and present an update on their drug candidate.
BELLUS Health (TSX:BLU) announced it will host a “Key Opinion Leader” event focused on the treatment of a chronic cough and present an update on their drug candidate.
As quoted in the press release:
The event will feature a presentation by KOL Dr. Jacky Smith, Professor of Respiratory Medicine at the University of Manchester and Director of the NIHR South Manchester Respiratory and Allergy Clinical Research Facility. Dr. Smith will discuss the clinical presentation of chronic cough, its current unmet medical need and therapeutic options as well as novel treatment approaches under development.
Dr. Denis Garceau, BELLUS Health’s Senior Vice President, Drug Development, will also provide an update on BLU-5937, including results from preclinical studies and its development path.
Click here to read the full press release.
Source: www.newswire.ca
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.